aTYR PHARMA INC

ATYR ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013
Operating Activities
Net Income $-48.2M $-57.9M $-48.0M $-24.4M $-20.0M
Depreciation & Amortization $713.0K $900.0K $869.0K $829.0K $714.0K
Depreciation
Amortization
Stock-Based Compensation
Net Cash from Operating Activities $-42.4M $-52.9M $-36.8M $-22.8M $-17.3M
Investing Activities
Capital Expenditures $1.3M $600.0K $664.0K $249.0K $644.0K
Business Acquisitions
Net Cash from Investing Activities $-27.6M $33.5M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $52.7M $4.7M
Net Change in Cash $-17.3M $-14.6M $39.1M $-22.6M $32.8M
Free Cash Flow $-43.7M $-53.5M $-37.5M $-23.1M $-18.0M
← Newer Page 2 of 2 Older →